FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Virginia Clements

Research Profile

Living Beings

Chemicals & Drugs

Anatomy

Physiology

Disorders

Procedures

Neoplasm Transplantation

Co-author Network

Publications

TOP 3
Suzanne Ostrand-Rosenberg; Pratima Sinha; Daniel W Beury; Virginia K Clements
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.
Pratima Sinha; Olesya Chornoguz; Virginia K Clements; Konstantin A Artemenko; Roman A Zubarev; Suzanne Ostrand-Rosenberg
Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL.
Minu K Srivastava; Pratima Sinha; Virginia K Clements; Paulo Rodriguez; Suzanne Ostrand-Rosenberg
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Virginia Clements (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Suzanne Ostrand-Rosenberg; Pratima Sinha; Daniel W Beury; Virginia K Clements
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.
Seminars in cancer biology 2012;22(4):275-81.
2011: Pratima Sinha; Olesya Chornoguz; Virginia K Clements; Konstantin A Artemenko; Roman A Zubarev; Suzanne Ostrand-Rosenberg
Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL.
Blood 2011;117(20):5381-90.
2010: Minu K Srivastava; Pratima Sinha; Virginia K Clements; Paulo Rodriguez; Suzanne Ostrand-Rosenberg
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.
Cancer research 2010;70(1):68-77.
2009: Erica M Hanson; Virginia K Clements; Pratima Sinha; Dan Ilkovitch; Suzanne Ostrand-Rosenberg
Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells.
Journal of immunology (Baltimore, Md. : 1950) 2009;183(2):937-44.
2009: Stephanie K Bunt; Virginia K Clements; Erica M Hanson; Pratima Sinha; Suzanne Ostrand-Rosenberg
Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4.
Journal of leukocyte biology 2009;85(6):996-1004.
2008: James A Thompson; Minu K Srivastava; Jacobus Bosch; Virginia K Clements; Bruce R Ksander; Suzanne Ostrand-Rosenberg
The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
Cancer immunology, immunotherapy : CII 2008;57(3):389-98.
2007: Stephanie K Bunt; Linglin Yang; Pratima Sinha; Virginia K Clements; Jeff Leips; Suzanne Ostrand-Rosenberg
Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.
Cancer research 2007;67(20):10019-26.
2007: Pratima Sinha; Virginia K Clements; Stephanie K Bunt; Steven M Albelda; Suzanne Ostrand-Rosenberg
Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(2):977-83.
2007: Pratima Sinha; Virginia K Clements; Amy M Fulton; Suzanne Ostrand-Rosenberg
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.
Cancer research 2007;67(9):4507-13.
2006: Stephanie K Bunt; Pratima Sinha; Virginia K Clements; Jeff Leips; Suzanne Ostrand-Rosenberg
Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(1):284-90.
2005: Pratima Sinha; Virginia K Clements; Suzanne Ostrand-Rosenberg
Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.
Cancer research 2005;65(24):11743-51.
2005: Pratima Sinha; Virginia K Clements; Seth Miller; Suzanne Ostrand-Rosenberg
Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression.
Cancer immunology, immunotherapy : CII 2005;54(11):1137-42.
2005: Pratima Sinha; Virginia K Clements; Suzanne Ostrand-Rosenberg
Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(2):636-45.
2004: Erika A Danna; Pratima Sinha; Mileka Gilbert; Virginia K Clements; Beth A Pulaski; Suzanne Ostrand-Rosenberg
Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease.
Cancer research 2004;64(6):2205-11.
2004: Samudra K Dissanayake; James A Thompson; Jacobus Bosch; Virginia K Clements; Peter W Chen; Bruce R Ksander; Suzanne Ostrand-Rosenberg
Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy.
Cancer research 2004;64(5):1867-74.
2004: Suzanne Ostrand-Rosenberg; Pratima Sinha; Virginia K Clements; Samudra I Dissanayake; Seth Miller; Cordula Davis; Erika A Danna
Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic disease.
Cancer immunology, immunotherapy : CII 2004;53(2):86-91.
2002: Suzanne Ostrand-Rosenberg; Virginia K Clements; Masaki Terabe; Jong Myun Park; Jay A Berzofsky; Samudra K Dissanayake
Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(10):5796-804.
2000: Suzanne Ostrand-Rosenberg; M J Grusby; Virginia K Clements
Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(11):6015-9.
2000: Beth A Pulaski; Virginia K Clements; M R Pipeling; Suzanne Ostrand-Rosenberg
Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.
Cancer immunology, immunotherapy : CII 2000;49(1):34-45.
1999: Suzanne Ostrand-Rosenberg; Beth A Pulaski; Virginia K Clements; Ling Qi; M R Pipeling; Laura Hanyok
Cell-based vaccines for the stimulation of immunity to metastatic cancers.
Immunological reviews 1999;170():101-14.
1998: TD Armstrong; Virginia K Clements; Suzanne Ostrand-Rosenberg
Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(3):218-24.
1998: TD Armstrong; Virginia K Clements; Suzanne Ostrand-Rosenberg
MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(2):661-6.
1998: Suzanne Ostrand-Rosenberg; Beth A Pulaski; TD Armstrong; Virginia K Clements
Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines.
Advances in experimental medicine and biology 1998;451():259-64.
1997: Tom Li Stephen; ST Smiley; AM Ranger; Virginia K Clements; Suzanne Ostrand-Rosenberg; Laurie H Glimcher
Single amino acid mutations in the murine MHC class II A beta cytoplasmic domain abrogate antigen presentation.
Journal of immunology (Baltimore, Md. : 1950) 1997;159(12):5914-20.
1997: TD Armstrong; Virginia K Clements; B K Martin; Jenny P-Y Ting; Suzanne Ostrand-Rosenberg
Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(13):6886-91.
1996: S Baskar; Virginia K Clements; Laurie H Glimcher; N Nabavi; Suzanne Ostrand-Rosenberg
Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(10):3821-7.
1996: Suzanne Ostrand-Rosenberg; S Baskar; N Patterson; Virginia K Clements
Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
Tissue antigens 1996;47(5):414-21.
1993: E Lamousé-Smith; Virginia K Clements; Suzanne Ostrand-Rosenberg
Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(11):6283-90.
1992: Virginia K Clements; S Baskar; TD Armstrong; Suzanne Ostrand-Rosenberg
Invariant chain alters the malignant phenotype of MHC class II+ tumor cells.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(7):2391-6.
1991: Suzanne Ostrand-Rosenberg; C A Roby; Virginia K Clements
Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule.
Journal of immunology (Baltimore, Md. : 1950) 1991;147(7):2419-22.
1991: Suzanne Ostrand-Rosenberg; E P Garcia; C A Roby; Virginia K Clements
Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejection.
Seminars in cancer biology 1991;2(5):311-9.
1991: Suzanne Ostrand-Rosenberg; C Roby; Virginia K Clements; G A Cole
Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1991;6():61-8.
1990: Suzanne Ostrand-Rosenberg; G A Cole; Michael I Nishimura; Virginia K Clements
Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous host.
Cellular immunology 1990;128(1):152-64.
1990: Suzanne Ostrand-Rosenberg; A Thakur; Virginia K Clements
Rejection of mouse sarcoma cells after transfection of MHC class II genes.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(10):4068-71.
1989: Suzanne Ostrand-Rosenberg; Virginia K Clements; A Thakur; G A Cole
Transfection of major histocompatibility complex class I and class II genes causes tumour rejection.
Journal of immunogenetics 1989;16(4-5):343-9.
1989: Suzanne Ostrand-Rosenberg; D A Nickerson; Virginia K Clements; E P Garcia; E Lamouse-Smith; L Hood; I Stroynowski
Embryonal carcinoma cells express Qa and Tla class I genes of the major histocompatibility complex.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(13):5084-8.
1987: G A Cole; G A Cole; Virginia K Clements; E P Garcia; Suzanne Ostrand-Rosenberg
Allogeneic H-2 antigen expression is insufficient for tumor rejection.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(23):8613-7.
1987: Suzanne Ostrand-Rosenberg; Virginia K Clements
Resistance to 402AX teratocarcinoma involves immunity to minor histocompatibility antigens.
Immunogenetics 1987;26(1-2):1-5.
1986: Suzanne Ostrand-Rosenberg; Virginia K Clements; L Marr
402AX teratocarcinoma MHC class I antigen expression is regulated in vivo by Lyt 1, Lyt 2, and L3T4 expressing splenic T cells.
Cellular immunology 1986;98(2):257-65.
1984: Suzanne Ostrand-Rosenberg; Virginia K Clements; G Cole; A DeCloux; L Marr; M Schwartzman
Regulation of major histocompatibility gene expression in teratocarcinoma 402AX cells.
Cell differentiation 1984;15(2-4):221-7.